Latest News and Press Releases

Findings show roluperidone increases release and gene expression of BDNF, as well as release of GDNF Data presented at 2019 Congress of the Schizophrenia International Research Society WALTHAM,...

Decision Resources Group to provide review of the disease landscape and forecast Key opinion leader to discuss negative symptoms in schizophrenia Minerva to outline roluperidone’s potential position...

Recruitment active in five late-stage trials with three compounds directed toward significant unmet medical needs Target indications include schizophrenia, major depressive disorder and insomnia...

WALTHAM, Mass., March 05, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...

WALTHAM, Mass., Nov. 28, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...

WALTHAM, Mass., Nov. 21, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...

Findings suggest expanded therapeutic window and significantly improved cardiovascular safety margin compared to formulation used in Phase 2b trial  All doses tested up to 256 milligrams appear safe...

Minerva management to provide update on Phase 3 clinical trial with roluperidone and single-dose escalation study findings Additional topics to include review of recent BDNF data with roluperidone...

WALTHAM, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...

Data readouts from five ongoing late-stage trials expected in 2019 WALTHAM, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical...